3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Brain Neoplasms
129
Neoplasm Metastasis
33
Glioblastoma
24
Melanoma
22
Lung Neoplasms
16
Carcinoma, Non-Small-Cell Lung
16
Breast Neoplasms
15
Glioma
12
Small Cell Lung Carcinoma
8
Neoplasms
8
Gliosarcoma
8
Central Nervous System Neoplasms
7
Neuroma, Acoustic
6
Meningioma
6
Carcinoma, Renal Cell
6
Astrocytoma
5
Spinal Cord Neoplasms
4
Recurrence
4
Sarcoma
3
Oligodendroglioma
3
Gastrointestinal Neoplasms
3
Breast Neoplasms, Male
3
Uveal Melanoma
2
Radiation Injuries
2
Prostatic Neoplasms
2
Kidney Neoplasms
2
Fatigue
2
Depression
2
Colorectal Neoplasms
2
Anxiety Disorders
2
Interventions
Bevacizumab
4
Temozolomide
3
Irinotecan
3
Sorafenib
2
pembrolizumab
1
ibrutinib
1
Vorinostat
1
Valproic Acid
1
Transcranial Magnetic Stimulation
1
Therapeutics
1
Thalidomide
1
Surveys and Questionnaires
1
Sildenafil Citrate
1
Radiosurgery
1
Pliability
1
Palliative Care
1
Lenalidomide
1
Laparoscopy
1
Exercise
1
Equipment and Supplies
1
Carboplatin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurologic Manifestations
×
Radiosurgery
×
CNS
×
Clear all
NCT01120639
2021-08-06
Tx-Treatment
Stanford University
Phase 1/2
Completed
30 enrolled
19 charts